Matches in Wikidata for { <http://www.wikidata.org/entity/Q105088552> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q105088552 description "clinical trial" @default.
- Q105088552 description "ensayo clínico" @default.
- Q105088552 description "ensayu clínicu" @default.
- Q105088552 description "klinisch onderzoek" @default.
- Q105088552 description "клінічне випробування" @default.
- Q105088552 description "临床试验" @default.
- Q105088552 name "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)" @default.
- Q105088552 name "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)" @default.
- Q105088552 type Item @default.
- Q105088552 label "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)" @default.
- Q105088552 label "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)" @default.
- Q105088552 prefLabel "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)" @default.
- Q105088552 prefLabel "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)" @default.
- Q105088552 P1132 Q105088552-DF6FE396-04E7-4BC1-832E-9BF658E4B99E @default.
- Q105088552 P1476 Q105088552-E14F63B5-E697-48F8-9C87-4A45CD8E434C @default.
- Q105088552 P1813 Q105088552-0D56E55A-2595-4002-A4ED-9B9AC13284E1 @default.
- Q105088552 P2899 Q105088552-25740FDD-27CE-49C5-86BA-81C4E96708CE @default.
- Q105088552 P3098 Q105088552-82899CAF-E247-4B7D-BE97-84C6921A1118 @default.
- Q105088552 P31 Q105088552-ADAFBC05-710B-4D43-9235-9BE83A5B0094 @default.
- Q105088552 P4844 Q105088552-B68A74D0-1084-4D31-B678-1E9150468EDC @default.
- Q105088552 P4844 Q105088552-EA84144E-0638-4205-9188-652E4EB99C10 @default.
- Q105088552 P580 Q105088552-83B7E7CE-8370-4211-AFED-9C687EF5155A @default.
- Q105088552 P582 Q105088552-D7DCE877-CEB4-4E27-A0EE-CFA5347A0175 @default.
- Q105088552 P6099 Q105088552-0FD49999-5AEB-45C5-82CA-01EA7CE42B0E @default.
- Q105088552 P8005 Q105088552-A3F56608-C84F-42A7-9940-C038124C9BCC @default.
- Q105088552 P8363 Q105088552-B39622BF-38FC-4AA5-82EC-6AC984C9D072 @default.
- Q105088552 P859 Q105088552-6AEA17E3-6C7F-49EB-AAD9-C6E9A0A78DA8 @default.
- Q105088552 P1132 "+1500" @default.
- Q105088552 P1476 "A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 Infection" @default.
- Q105088552 P1813 "Impower-024" @default.
- Q105088552 P2899 "+16" @default.
- Q105088552 P3098 "NCT04652700" @default.
- Q105088552 P31 Q30612 @default.
- Q105088552 P4844 Q155954 @default.
- Q105088552 P4844 Q422604 @default.
- Q105088552 P580 "2021-03-08T00:00:00Z" @default.
- Q105088552 P582 "2024-01-02T00:00:00Z" @default.
- Q105088552 P6099 Q42824827 @default.
- Q105088552 P8005 Q76649614 @default.
- Q105088552 P8363 Q78089383 @default.
- Q105088552 P859 Q58219685 @default.